Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The final study sample comprised 8,797 participants (53.5% women, mean age at HUNT4 77.8 [SD 6.2]). Of these, 2,649 (30.1%) were p-tau217-positive and 659 (7%) had biomarker-verified AD dementia. Midlife WtHR ≥0.60 was associated with 12.8% (95% CI 7.3-19.7) higher late-life p-tau217 concentration and higher risk of positive p-tau217 (relative risk ratios [RRRs] 1.55, 1.21-1.99) and biomarker-verified AD dementia (RRR 1.84, 1.27-2.65) compared with WtHR <0.50. In late life, WtHR ≥0.60 was associated with 15.6% (-19.0 to -12.2) lower p-tau217 concentration and lower risk of positive p-tau217 (RRR 0.49, 0.41-0.59) and biomarker-verified AD dementia (RRR 0.63, 0.46-0.86). BMI showed similar patterns: Midlife obesity was associated with higher p-tau217 concentration and elevated risk of biomarker-verified AD dementia, whereas late-life overweight/obesity was associated with lower p-tau217 and decreased risk of biomarker-verified AD dementia. Among those with positive p-tau217 or biomarker-verified AD dementia, mixed-effects regression showed higher midlife adiposity, reversing by late life. Our results identify midlife central and general adiposity as modifiable risk factors for AD pathology and AD dementia. WtHR may aid early risk stratification and inform interventions targeting central fat reduction.

What this study adds

Evidence grade: Low

The record lists 8,797 participants. Midlife central and general adiposity were linked to higher late-life p-tau217 and higher risk of biomarker-verified AD dementia, while late-life adiposity showed the opposite pattern. Reported effect size: 53.5%; 30.1%; 12.8%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zotcheva, E., Strand, B. H., Sunde, A. L., Deckers, K., Aarsland, D., Ashton, N. J., et al. (2026). Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia. Neurology. https://doi.org/10.1212/wnl.0000000000218093

Vancouver

Zotcheva E, Strand BH, Sunde AL, Deckers K, Aarsland D, Ashton NJ, et al. Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia. Neurology. 2026. doi:10.1212/wnl.0000000000218093. PMID: 42228892.

BibTeX

@article{zotcheva2026-42228892,
  author  = {Zotcheva, Ekaterina and Strand, Bjørn Heine and Sunde, Anita Lenora and Deckers, Kay and Aarsland, Dag and Ashton, Nicholas James and Zetterberg, Henrik and Skirbekk, Vegard and others},
  title   = {{Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia}},
  journal = {Neurology},
  year    = {2026},
  doi     = {10.1212/wnl.0000000000218093},
  pmid    = {42228892},
  url     = {https://doi.org/10.1212/wnl.0000000000218093}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Midlife central and general adiposity were linked to higher late-life p-tau217 and higher risk of biomarker-verified AD dementia, while late-life adiposity showed the opposite pattern. The authors identify midlife central and general adiposity as modifiable risk factors for AD pathology and dementia.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 8,797 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Geir Selbæk: h-index 61 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 27 institution(s) in 9 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42228892)
Free to read 0 / 2 Behind a paywall — scores zero
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Related studies in Biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →